Symbols / ELOX
ELOX Chart
About
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bullosa; and ZKN013, which is in investigation phase for the treatment of nonsense mutation familial adenomatous polyposis. It also offers platform technologies, including Turbo-ZM and Ribosome Modulating Agents; and Eukaryotic Ribosomal Selective Glycosides for the treatment of rare and ultra-rare premature stop codon diseases. The company is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 314.00 |
| Enterprise Value | 13.95M | Income | -20.48M | Sales | — |
| Book/sh | -6.53 | Cash/sh | 1.52 | Dividend Yield | — |
| Payout | 0.00% | Employees | 18 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.72 | EV/Sales | — | Quick Ratio | 0.20 |
| Current Ratio | 0.24 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -8.88 | EPS next Y | -0.71 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-11-13 16:00 | ROA | -73.24% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.14M |
| Shs Float | 2.91M | Short Float | 0.80% | Short Ratio | 0.66 |
| Short Interest | — | 52W High | 0.75 | 52W Low | 0.00 |
| Beta | -171336.88 | Avg Volume | 966.00 | Volume | 343.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-47.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-07-11 | main | Oppenheimer | Outperform → Outperform | $55 |
| 2023-04-06 | reit | Oppenheimer | — → Outperform | $50 |
- Eloxx Pharmaceuticals: Tiny Stock, Big Volatility – What The Market Is Really Pricing In - AD HOC NEWS Sun, 01 Feb 2026 08
- Eloxx Pharmaceuticals enacts option repricing for CEO - Investing.com hu, 17 Oct 2024 07
- Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor - Nasdaq ue, 05 Dec 2023 08
- Eloxx Pharmaceuticals Announces Uplisting to Nasdaq and Pricing of $50 Million Public Offering of Common Stock - GlobeNewswire Wed, 25 Apr 2018 07
- The Wild Story Behind Eloxx Pharmaceuticals: Penny-Stock Zombie or Next Big Biotech Comeback? - AD HOC NEWS Sat, 17 Jan 2026 08
- Interesting LOW Put And Call Options For January 2026 - Nasdaq hu, 04 Dec 2025 08
- Eloxx Pharmaceuticals Acquires Zikani Therapeutics - GlobeNewswire hu, 01 Apr 2021 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 30000 | — | — | AGGARWAL SUMIT | Director | — | 2025-01-24 00:00:00 | D | nan |
| 1 | 3750 | — | — | WALTS ALAN EDMUND PH.D. | Director | — | 2025-01-24 00:00:00 | D | nan |
| 2 | 3750 | — | — | ANDROSKI LINDSAY J.D. | Director | — | 2025-01-24 00:00:00 | D | nan |
| 3 | 3750 | — | — | RUBIN STEVEN DANIEL | Director | — | 2025-01-24 00:00:00 | D | nan |
| 4 | 165000 | — | Stock Award(Grant) at price 0.00 per share. | AGGARWAL SUMIT | Chief Executive Officer | — | 2024-10-16 00:00:00 | D | — |
| 5 | 12000 | — | Stock Award(Grant) at price 0.00 per share. | WALTS ALAN EDMUND PH.D. | Director | — | 2024-10-16 00:00:00 | D | — |
| 6 | 12000 | — | Stock Award(Grant) at price 0.00 per share. | ANDROSKI LINDSAY J.D. | Director | — | 2024-10-16 00:00:00 | D | — |
| 7 | 12000 | — | Stock Award(Grant) at price 0.00 per share. | RUBIN STEVEN DANIEL | Director | — | 2024-10-16 00:00:00 | D | — |
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 |
| NormalizedEBITDA | -33.37M | -65.05M |
| TotalUnusualItems | -48.00K | 542.00K |
| TotalUnusualItemsExcludingGoodwill | -48.00K | 542.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -36.06M | -66.73M |
| ReconciledDepreciation | 695.00K | 960.00K |
| EBITDA | -33.42M | -64.51M |
| EBIT | -34.12M | -65.47M |
| NetInterestIncome | -1.68M | -1.25M |
| InterestExpense | 1.95M | 1.26M |
| InterestIncome | 274.00K | 8.00K |
| NormalizedIncome | -36.02M | -67.27M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -36.06M | -66.73M |
| TotalExpenses | 34.42M | 66.02M |
| TotalOperatingIncomeAsReported | -34.42M | -66.02M |
| DilutedAverageShares | 2.17M | 1.75M |
| BasicAverageShares | 2.17M | 1.75M |
| DilutedEPS | -16.65 | -38.00 |
| BasicEPS | -16.65 | -38.00 |
| DilutedNIAvailtoComStockholders | -36.06M | -66.73M |
| NetIncomeCommonStockholders | -36.06M | -66.73M |
| NetIncome | -36.06M | -66.73M |
| NetIncomeIncludingNoncontrollingInterests | -36.06M | -66.73M |
| NetIncomeContinuousOperations | -36.06M | -66.73M |
| PretaxIncome | -36.06M | -66.73M |
| OtherIncomeExpense | 29.00K | 542.00K |
| OtherNonOperatingIncomeExpenses | 77.00K | |
| SpecialIncomeCharges | 0.00 | 540.00K |
| OtherSpecialCharges | -540.00K | |
| RestructuringAndMergernAcquisition | 0.00 | |
| GainOnSaleOfSecurity | -48.00K | 2.00K |
| NetNonOperatingInterestIncomeExpense | -1.68M | -1.25M |
| InterestExpenseNonOperating | 1.95M | 1.26M |
| InterestIncomeNonOperating | 274.00K | 8.00K |
| OperatingIncome | -34.42M | -66.02M |
| OperatingExpense | 34.42M | 66.02M |
| ResearchAndDevelopment | 23.73M | 45.57M |
| SellingGeneralAndAdministration | 10.69M | 20.45M |
| GeneralAndAdministrativeExpense | 10.69M | 20.45M |
| OtherGandA | 10.69M | 20.45M |
| TotalRevenue | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TreasurySharesNumber | 0.00 | 10.53K |
| OrdinarySharesNumber | 2.17M | 2.17M |
| ShareIssued | 2.17M | 2.18M |
| TotalDebt | 13.38M | 13.46M |
| TangibleBookValue | -10.66M | 22.38M |
| InvestedCapital | 1.88M | 34.38M |
| WorkingCapital | -2.96M | 33.52M |
| NetTangibleAssets | -10.66M | 22.38M |
| CapitalLeaseObligations | 847.00K | 1.46M |
| CommonStockEquity | -10.66M | 22.38M |
| TotalCapitalization | -2.10M | 34.38M |
| TotalEquityGrossMinorityInterest | -10.66M | 22.38M |
| StockholdersEquity | -10.66M | 22.38M |
| TreasuryStock | 0.00 | 2.19M |
| RetainedEarnings | -274.39M | -238.32M |
| AdditionalPaidInCapital | 263.71M | 262.88M |
| CapitalStock | 22.00K | 22.00K |
| CommonStock | 22.00K | 22.00K |
| PreferredStock | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 31.78M | 22.75M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 8.69M | 12.80M |
| LongTermDebtAndCapitalLeaseObligation | 8.69M | 12.80M |
| LongTermCapitalLeaseObligation | 135.00K | 804.00K |
| LongTermDebt | 8.56M | 12.00M |
| CurrentLiabilities | 23.09M | 9.96M |
| OtherCurrentLiabilities | 45.00K | 3.72M |
| CurrentDeferredLiabilities | 12.54M | 3.72M |
| CurrentDeferredRevenue | 12.54M | 3.72M |
| CurrentDebtAndCapitalLeaseObligation | 4.69M | 657.00K |
| CurrentCapitalLeaseObligation | 712.00K | 657.00K |
| CurrentDebt | 3.98M | |
| OtherCurrentBorrowings | 3.98M | |
| PayablesAndAccruedExpenses | 5.82M | 5.58M |
| CurrentAccruedExpenses | 2.80M | 4.20M |
| InterestPayable | 146.00K | 102.00K |
| Payables | 3.02M | 1.38M |
| DuetoRelatedPartiesCurrent | 3.72M | |
| AccountsPayable | 3.02M | 1.38M |
| TotalAssets | 21.12M | 45.14M |
| TotalNonCurrentAssets | 994.00K | 1.66M |
| NetPPE | 994.00K | 1.66M |
| AccumulatedDepreciation | -180.00K | -171.00K |
| GrossPPE | 1.17M | 1.83M |
| Leases | 57.00K | 88.00K |
| ConstructionInProgress | 0.00 | 20.00K |
| OtherProperties | 1.08M | 1.66M |
| MachineryFurnitureEquipment | 41.00K | 58.00K |
| Properties | 0.00 | 0.00 |
| CurrentAssets | 20.13M | 43.48M |
| OtherCurrentAssets | 568.00K | 790.00K |
| RestrictedCash | 261.00K | 299.00K |
| PrepaidAssets | 93.00K | 123.00K |
| CashCashEquivalentsAndShortTermInvestments | 19.21M | 42.27M |
| CashAndCashEquivalents | 19.21M | 42.27M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | -31.91M | -35.09M |
| RepaymentOfDebt | 0.00 | -11.38M |
| IssuanceOfDebt | 0.00 | 11.87M |
| IssuanceOfCapitalStock | 0.00 | 47.72M |
| CapitalExpenditure | -66.00K | -89.00K |
| InterestPaidSupplementalData | 1.36M | 728.00K |
| IncomeTaxPaidSupplementalData | 0.00 | |
| EndCashPosition | 19.47M | 42.57M |
| BeginningCashPosition | 42.57M | 24.72M |
| ChangesInCash | -23.10M | 17.84M |
| FinancingCashFlow | 8.81M | 50.79M |
| CashFlowFromContinuingFinancingActivities | 8.81M | 50.79M |
| NetOtherFinancingCharges | 8.81M | 2.56M |
| ProceedsFromStockOptionExercised | 0.00 | 23.00K |
| NetCommonStockIssuance | 0.00 | 47.72M |
| CommonStockIssuance | 0.00 | 47.72M |
| NetIssuancePaymentsOfDebt | 0.00 | 491.00K |
| NetLongTermDebtIssuance | 0.00 | 491.00K |
| LongTermDebtPayments | 0.00 | -11.38M |
| LongTermDebtIssuance | 0.00 | 11.87M |
| InvestingCashFlow | -66.00K | 2.06M |
| CashFlowFromContinuingInvestingActivities | -66.00K | 2.06M |
| NetInvestmentPurchaseAndSale | 0.00 | |
| SaleOfInvestment | 0.00 | |
| PurchaseOfInvestment | 0.00 | |
| NetBusinessPurchaseAndSale | 0.00 | 2.15M |
| SaleOfBusiness | 0.00 | 2.15M |
| NetPPEPurchaseAndSale | -66.00K | -89.00K |
| SaleOfPPE | 0.00 | |
| PurchaseOfPPE | -66.00K | -89.00K |
| OperatingCashFlow | -31.84M | -35.00M |
| CashFlowFromContinuingOperatingActivities | -31.84M | -35.00M |
| ChangeInWorkingCapital | -118.00K | -32.00K |
| ChangeInOtherCurrentLiabilities | -614.00K | -829.00K |
| ChangeInPayablesAndAccruedExpense | 244.00K | 215.00K |
| ChangeInAccruedExpense | -1.40M | 535.00K |
| ChangeInPayable | 1.64M | -320.00K |
| ChangeInAccountPayable | 1.64M | -320.00K |
| ChangeInPrepaidAssets | 252.00K | 582.00K |
| OtherNonCashItems | 541.00K | 22.09M |
| StockBasedCompensation | 3.02M | 9.17M |
| AssetImpairmentCharge | 36.00K | 0.00 |
| AmortizationOfSecurities | 0.00 | |
| DepreciationAmortizationDepletion | 695.00K | 960.00K |
| DepreciationAndAmortization | 695.00K | 960.00K |
| Depreciation | 695.00K | 960.00K |
| OperatingGainsLosses | 45.00K | -456.00K |
| GainLossOnInvestmentSecurities | 45.00K | |
| GainLossOnSaleOfPPE | 0.00 | 84.00K |
| NetIncomeFromContinuingOperations | -36.06M | -66.73M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ELOX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|